Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Advances that have been made in the molecular characterization of multiple myeloma

Mark Bustoros • 27 Sep 2023
IMS 2023
Multiple Myeloma

In this video, Mark Bustoros, MD, Weill Cornell Medicine, New York City, NY, discusses advances that have been made in the molecular characterization of multiple myeloma, including epigenetic characterization. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mark Bustoros

3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
1:50
Molecular characteristics of extramedullary myeloma
Mark Bustoros • 27 Sep 2023
1:30
Evolution in myeloma therapy
Mark Bustoros • 14 Oct 2021

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals